[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120;  121-140141-160;  161-180181-200201-220221-240241-260261-280; 281+

NICE TAs 121-140

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA121

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)    

   

EMCN algorithm

DHFT protocol

TA122

Ischaemic stroke (acute) - alteplase (TA122) (replaced by TA264)

Withdrawn

 

TA123

Smoking cessation - varenicline (TA123)

4.10 Substance abuse

 

TA124

Lung cancer (non-small-cell) - pemetrexed (TA124)

 

EMCN algorithm

DHFT protocol

TA125

Psoriatic arthritis (moderate to severe) - adalimumab (TA125) (replaced by TA199)

Withdrawn

 

TA126

Rheumatoid arthritis (refractory) - rituximab (TA126) (replaced by TA195)

Withdrawn

 

TA127 

Multiple sclerosis - natalizumab (TA127)  

8.2 Drugs affecting the immune response

 

TA128

Haemorrhoid - stapled haemorroidopexy (TA128)

No drug implications

 

TA129

Multiple myeloma - bortezomib (TA129)

 

EMCN algorithm

DHFT protocol

TA130

Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)  

10.1.2 - 10.1.3 Corticosteroids, rheumatic disease suppressants, gout

 

TA131

Asthma (in children) - corticosteroids (TA131)

3.2 Corticosteroids

 

TA132

Hypercholesterolaemia - ezetimibe (TA132)

2.12 Lipid lowering drugs

 

TA133

Asthma (uncontrolled) - omalizumab (TA133) 

Has been replaced by:

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)

3.4 Antihistamines: 3.4.3 Allergen Immunotherapy

 

TA134

Psoriasis - infliximab (TA134)

13.5.3 Drugs affecting the immune response

 

TA135

Mesothelioma - pemetrexed disodium (TA135)

 

EMCN algorithm

DHFT protocol

TA136 

Structural neuroimaging in first-episode psychosis (TA136) 

No drug implications

 

TA137

Lymphoma (follicular non-Hodgkin's) - rituximab (TA137)

8.2 Drugs affecting the immune response: 8.2.3 Rituximab & Alemtuzumab

EMCN algorithm

DHFT protocol 

TA138

Asthma (in adults) - corticosteroids (TA138)

3.2 Corticosteroids

 

TA139

Sleep apnoea - continuous positive airway pressure (CPAP) (TA139)

No drug implications

 

TA140

Ulcerative colitis (subacute manifestations) - infliximab (TA140)

No drug implications